IGC Insider Trading Activity and SEC Form 4 Filings
IGC insider trading summary
No open-market insider purchases or sales of IGC Pharma, Inc. (IGC) have been reported on SEC Form 4 in the past 12 months.
Latest IGC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 25, 2024 | James P Moran | Director | Buy | $200K (588,235 @ $0.34) |
| Mar 9, 2021 | Richard K Prins | Director | Sell | $88K (50,000 @ $1.75) |
| Mar 3, 2021 | Richard K Prins | Director | Sell | $905 (500 @ $1.81) |
| Mar 3, 2021 | Richard K Prins | Director | Sell | $89K (49,500 @ $1.80) |
| Mar 2, 2021 | Ram Mukunda | Exec. Chairman & CEO | Sell | $107K (50,000 @ $2.14) |
| Dec 1, 2020 | Richard K Prins | Director | Sell | $102K (50,000 @ $2.04) |
| Nov 30, 2020 | Ram Mukunda | Exec. Chairman & CEO | Sell | $187K (80,000 @ $2.34) |
| Aug 30, 2018 | Ram Mukunda | Exec. Chairman & CEO | Sell | $93K (50,000 @ $1.87) |
| Aug 30, 2018 | Claudia Grimaldi | Vice President and PFO | Sell | $232K (116,020 @ $2.00) |
| Aug 28, 2018 | Ram Mukunda | Exec. Chairman & CEO | Sell | $166K (125,000 @ $1.33) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.